For seamless registration, login with your Medscape membership account. If you are not logged in, you can register as a guest.
HILTON CHICAGO
SUNDAY, JUNE 2, 2024 | 6:45 PM - 7:45 PM CT
Join us for a symposium on bispecific antibodies for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) designed to encourage the exchange of ideas between leaders in the field and attendees. Experts in the field will discuss clinical trial data, adverse event management, and the current treatment landscape for bispecific antibodies in relapsed-refractory (R/R) DLBCL. This program will include a dynamic expert discussion and rapid-fire Q&A as well as an interactive audience Q&A.
Not an official event of the 2024 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer® the ASCO Foundation.
Deputy Chair, Section Chief, Indolent Lymphoma and New Drug Development, Director, Lymphoma Outcomes Database, The University of Texas MD Anderson Cancer Center, Houston, Texas
Reid Merryman, MD
PANELIST
Assistant Professor, Dana-Farber Cancer Institute, Boston, Massachusetts
Lorenzo Falchi, MD
PANELIST
Assistant Attending, Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, New York
